Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer

Journal of Investigative Dermatology

Volumn 129, Issue 7, 2009, Pages 1816-1823

  Bocheva, Georgeta ^a   Rattenholl, Anke ^b,c   Kempkes, Cordula ^b   Goerge, Tobias ^b   Lin, Chen Yong ^d   D'Andrea, Michael R ^e   Ständer, Sonja ^b   Steinhoff, Martin ^b,c,f  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b INST OF REPRO MED OF THE UNIV   (Germany)

^c Interdisciplinary Centre of Clinical Research (IZKF)   (Germany)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; MATRIPTASE; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 2; RNA; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CALCIUM MOBILIZATION; CANCER GROWTH; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

EID: 67449116587     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.449     Document Type: Article

References (29)

1. Benaud CM, Oberst M, Dickson RB, Lin CY (2002) Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 19:639-49
2. Bohm SK, Kong W, Bramme D, Smeekens SP, Anderson DC, Connolly A et al. (1996) Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 314:1009-16
3. Cheng MF, Tzao C, Tsai WC, Lee WH, Chen A, Chiang H et al. (2006) Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus 19:482-6
4. Demerjian M, Hachem JP, Tschachler E, Denecker G, Declercq W, Vandenabeele P et al. (2008) Acute modulations in permeability barrier function regulate epidermal comification: role of caspase-14 and the protease-activated receptor type 2. Am J Pathol 172:86-97
5. Derian CK, Eckardt AJ, Andrade-Gordon P (1997) Differential regulation of human keratinocyte growth and differentiation by a novel family of protease-activated receptors. Cell Growth Differ 8:743-9
6. Hachem JP, Houben E, Crumrine D, Man MQ, Schurer N, Roelandt T et al. (2006) Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 126:2074-86
7. Jeong SK, Kim HJ, Youm JK, Ahn SK, Choi EH, Sohn MH et al. (2008) Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol 128:1930-9
8. Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF (2006a) Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 14:65-72
9. Jin JS, Hsieh DS, Loh SH, Chen A, Yao CW, Yen CY (2006b) Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathol 19:447-52
10. Jin JS, Cheng TF, Tsai WC, Sheu LF, Chiang H, Yu CP (2007) Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters. Histol Histopathol 22:305-9
11. Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS et al. (2005) Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 36:626-33
12. List K, Bugge TH, Szabo R (2006a) Matriptase: potent proteolysis on the cell surface. Mol Med 12:1-7
13. List K, Szabo R, Molinolo A, Nielsen BS, Bugge TH (2006b) Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 168:1513-25
14. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W et al. (2002) Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21:3765-79
15. List K, Szabo R, Wertz PW, Segre J, Haudenschild CC, Kim SY et al. (2003) Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol 163:901-10
16. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T et al. (2005) Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 19:1934-50
17. Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M et al. (2005) Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 36:676-85
18. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M et al. (2001) Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 158: 1301-11
19. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY (2003) Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 51:101 7-25
20. Rattenholl A, Seeliger S, Buddenkotte J, Schön M, Schön MP, Ständer S et al. (2007) Proteinase-activated receptor-2 (PAR2): a tumor suppressor in skin carcinogenesis. J Invest Dermatol 127:2245-52
21. Rattenholl A, Steinhoff M (2008) The role of proteinase-activated receptor-2 (PAR2) in the regulation of cytokine and chemokine expression in the skin. Drug News Perspect 21:369-81
22. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB et al. (2006) A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15:217-27
23. Sanders AJ, Parr C, Davies G, Martin TA, Lane J, Mason MD et al. (2006) Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. J Exp Ther Oncol 6:39-48
24. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N et al. (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1-43
25. Steinhoff M, Corvera CU, Thoma MS, Kong W, McAlpine BE, Caughey GH et al. (1999) Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol 8:282-94
26. Szabo R, Molinolo A, List K, Bugge TH (2007) Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 26:1546-56
27. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275:26333-42
28. Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS (2006) Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 49:388-95
29. Vogel LK, Saebo M, Skjelbred CF, Abell K, Pedersen ED, Vogel U et al. (2006) The ratio of matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer 6:176